Petra Tesarova

Summary

Country: Czech Republic

Publications

  1. ncbi request reprint Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management
    P Tesarova
    Department of Oncology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
    Folia Biol (Praha) 59:15-25. 2013
  2. ncbi request reprint [Soluble adhesion molecules in female patients with breast carcinoma]
    P Tesarova
    I interní klinika 1 LF UK a VFN, Praha
    Cas Lek Cesk 142:292-9. 2003
  3. ncbi request reprint [Acute phase proteins in female patients with breast carcinoma]
    P Tesarova
    Onkologická, Klinika, 1 lékarské fakulty Univerzity Karlovy a Vseobecné fakultní nemocnice, U nemocnice 2, 128 08 Praha 2, Czech Republic
    Sb Lek 104:121-32. 2003
  4. ncbi request reprint Carbonyl and oxidative stress in patients with breast cancer--is there a relation to the stage of the disease?
    P Tesarova
    Department of Oncology, 1st School of Medicine and General Faculty Hospital, Prague, Czech Republic
    Neoplasma 54:219-24. 2007
  5. ncbi request reprint Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer
    Petra Tesarová
    Department of Oncology, 1st School of Medicine, Charles University and General University Hospital, Prague, Czech Republic
    Cancer Invest 25:720-5. 2007
  6. ncbi request reprint Glyoxalase I Glu111Ala polymorphism in patients with breast cancer
    Alexandra Germanova
    Institute of Clinical Chemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
    Cancer Invest 27:655-60. 2009

Collaborators

  • M Kalousova
  • Tomas Zima
  • Alexandra Germanova
  • Petra Tesarová
  • Anna Germanova
  • Karel Zvara
  • Marie Jachymova
  • Marta Kalousová
  • Oto Mestek
  • Lubos Petruzelka
  • Marie Jáchymová

Detail Information

Publications6

  1. ncbi request reprint Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management
    P Tesarova
    Department of Oncology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
    Folia Biol (Praha) 59:15-25. 2013
    ..Hypertension caused by anti-VEGF therapy can be effectively treated; progression of proteinuria and/or renal dysfunction may require tapering, or even withdrawal of anti-VEGF treatment...
  2. ncbi request reprint [Soluble adhesion molecules in female patients with breast carcinoma]
    P Tesarova
    I interní klinika 1 LF UK a VFN, Praha
    Cas Lek Cesk 142:292-9. 2003
    ..We wanted to find out if these parameters differ between various stages of breast cancer and if their levels are influenced by the therapy...
  3. ncbi request reprint [Acute phase proteins in female patients with breast carcinoma]
    P Tesarova
    Onkologická, Klinika, 1 lékarské fakulty Univerzity Karlovy a Vseobecné fakultní nemocnice, U nemocnice 2, 128 08 Praha 2, Czech Republic
    Sb Lek 104:121-32. 2003
    ....
  4. ncbi request reprint Carbonyl and oxidative stress in patients with breast cancer--is there a relation to the stage of the disease?
    P Tesarova
    Department of Oncology, 1st School of Medicine and General Faculty Hospital, Prague, Czech Republic
    Neoplasma 54:219-24. 2007
    ..Serum concentrations of AGEs in patients with breast cancer correlated with the age and also with the serum concentration of AOPP...
  5. ncbi request reprint Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer
    Petra Tesarová
    Department of Oncology, 1st School of Medicine, Charles University and General University Hospital, Prague, Czech Republic
    Cancer Invest 25:720-5. 2007
    ..Patients with better outcome (low grade and positive estrogen receptors) have higher sRAGE levels. Progression of the disease, may, however, increase sRAGE levels, possibly as a compensatory mechanism to counteract further progression...
  6. ncbi request reprint Glyoxalase I Glu111Ala polymorphism in patients with breast cancer
    Alexandra Germanova
    Institute of Clinical Chemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
    Cancer Invest 27:655-60. 2009
    ..05). The presence of the C allele could represent a negative prognostic factor; however, further studies are needed to confirm this hypothesis...